Pacira BioSciences Inc. (PCRX) reported fourth-quarter fiscal 2025 results with revenue of $196.9 million, up 5.1% year-over-year and above the revenue estimate of $176.8 million. Diluted earnings per share were $0.04, down 88.2% year-over-year and below the EPS estimate of $0.57.
Cash flow and balance sheet highlights show improved cash generation but a decline in cash on hand. Operating cash flow rose to $60.8 million (+83.61% YoY), capital expenditures were $3.9 million (+82.72% YoY), cash and cash equivalents totaled $158.5 million (−42.72% YoY), and total liabilities decreased to $372.2 million (−51.99% YoY).
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Pacira BioSciences Inc. Insider Trading Activity
Pacira BioSciences Inc. insiders have traded $PCRX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- SHAWN CROSS (Chief Financial Officer) has made 0 purchases and 7 sales selling 62,060 shares for an estimated $1,521,350.
- KRISTEN WILLIAMS (Chief Administrative Officer) sold 13,137 shares for an estimated $269,702
- JONATHAN SLONIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 7,221 shares for an estimated $169,812.
- LAUREN RIKER (Senior Vice President, Finance) has made 0 purchases and 2 sales selling 5,416 shares for an estimated $117,563.
- MARK FROIMSON sold 500 shares for an estimated $10,905
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Pacira BioSciences Inc. Hedge Fund Activity
We have seen 122 institutional investors add shares of Pacira BioSciences Inc. stock to their portfolio, and 123 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 939,092 shares (-49.8%) from their portfolio in Q4 2025, for an estimated $24,303,700
- CITADEL ADVISORS LLC added 748,590 shares (+1051.7%) to their portfolio in Q4 2025, for an estimated $19,373,509
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 482,105 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $12,476,877
- ASSENAGON ASSET MANAGEMENT S.A. removed 435,143 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9,834,231
- VANGUARD GROUP INC removed 384,612 shares (-7.4%) from their portfolio in Q4 2025, for an estimated $9,953,758
- HILLSDALE INVESTMENT MANAGEMENT INC. added 308,200 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,976,216
- UBS GROUP AG removed 296,210 shares (-34.7%) from their portfolio in Q4 2025, for an estimated $7,665,914
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Pacira BioSciences Inc. Analyst Ratings
Wall Street analysts have issued reports on $PCRX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/09/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/09/2026
- Truist Securities issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for Pacira BioSciences Inc., check out Quiver Quantitative's $PCRX forecast page.
Pacira BioSciences Inc. Price Targets
Multiple analysts have issued price targets for $PCRX recently. We have seen 4 analysts offer price targets for $PCRX in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $25.0 on 03/26/2026
- Serge Belanger from Needham set a target price of $30.0 on 01/09/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $38.0 on 01/09/2026
- Les Sulewski from Truist Securities set a target price of $28.0 on 11/07/2025
